Zio by iRhythm Technologies, Inc. news
iRhythm President and CEO Quentin Blackford sat down with Nasdaq’s Behind the Bell to discuss iRhythm’s patient-first mission to impact people across the globe, the opportunity to advance our innovative platform technology, and Nasdaq’s role in realizing our vision.<
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the results of four clinical studies presented at the American Heart Association’s (
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced a new health economic analysis of the
iRhythm Technologies will have the results of four studies presented by leading clinical investigators at the American Heart Association’s 2022 Scientific Sessions on Nov. 5-7 in Chicago, Illinois. The studies listed below focus on iRhythm’s core suite of Zio XT and AT patch-based extended and mobile cardiac monitoring products and services.
Saturday, Nov. 5
- 3:00 – 4:00 p.m. CDT – SA4182: “Ascension Health Syst
iRhythm is included in the Medtech Big 100, a ranking of the world’s largest medical device companies, for the second year in a row. Medical Design & Outsourcing says it evaluates companies for the list based on annual revenue, research and development spending, number of employees, key leaders, headquarters locations, and company descriptions.
Read the